Which fluoroquinolones are suitable for the treatment of urinary tract infections?
Which fluoroquinolones are suitable for the treatment of urinary tract infections?
复制标题
DOI：
10.1016/s0924-8579(00)00362-9
复制
发表时间：
2001-04-01
影响因子：
10.8
通讯作者：
Naber, KG
中科院分区：
文献类型：
--
作者：
Naber, KG
许多氟喹诺酮药物现在可用于临床使用，甚至更多的药物正在开发中。这些化合物在治疗尿路感染（UTI）中是否同样有效，因此可以互换，必须通过比较它们对尿路病原体的抗微生物活性来回答。：药代动力学和药效学参数以及具有统计学意义的临床研究结果。然而，几乎所有氟喹诺酮类药物与急性无并发症膀胱炎的短期治疗效果相当：对于女性，对于复杂性UTI患者，仅应选择适当剂量方案的化合物进行经验性治疗，这些化合物对革兰氏阴性和革兰氏阳性泌尿病原体表现出足够高的泌尿杀菌活性。当考虑到抗菌活性、药代动力学和药效学特性以及已发表的临床研究结果时，500 mg环丙沙星每日两次、500 mg左氧氟沙星每日一次或400 mg加替沙星每日一次的剂量方案可能是治疗重度复杂性UTI的相当剂量方案。在环丙沙星（750 mg，每日两次）和左氧氟沙星（500 mg，每日两次）的情况下，在由较不敏感的泌尿病原体引起的UTI中，剂量甚至可以增加。例如铜绿假单胞菌。(C)2001年Elsevier Science B.V.和国际化疗学会。All rights reserved.
A number of fluoroquinolone agents are now available for clinical use and even more under development. Whether these compounds are equally effective and thus interchangeable in the treatment of urinary tract infection (UTI) has to be answered by comparing their antimicrobial activity against uropathogens. the: pharmacokinetic and pharmacodynamic parameters and outcome of statistically meaningful clinical studies. Whereas almost all fluoroquinolones give equivalent results with short term therapy of acute uncomplicated cystitis: in women, for patients with complicated UTI, only those compounds at the appropriate dosage regimen should be chosen for empiric therapy, which would exhibit sufficiently high urinary bactericidal activity against Gram-negative as well as Gram-positive uropathogens. When considering antibacterial activity, pharmacokinetic and pharmacodynamic properties as well as the results of the published clinical studies, a dosage of 500 mg ciprofloxacin twice daily, 500 mg levofloxacin once daily, or 400 mg gatifloxacin once daily may be comparable dosage regimens in the treatment of severe complicated UTI. in the case of ciprofloxacin (750 mg twice daily) and levofloxacin (500 mg twice daily), the dose could even be increased in UTI caused by less susceptible uropathogens. such as Pseudomonas aeruginosa. (C) 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.